Phathom Pharmaceuticals, Inc. (PHAT) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	172.4	135.1	125.7	6.9	1.2
General and administrative				6.9	1.2
Research and development				20.4	0.0
Other operating expenses	24.0	8.0	3.2
EBITDA [+]	-195.8	-142.5	-128.5	-27.3
EBITDA growth	37.3%	10.9%	370.6%	2129.4%
Depreciation and amortization	0.6	0.5	0.3	0.0
EBIT [+]	-196.4	-143.1	-128.8	-27.3	-1.2
EBIT growth	37.3%	11.0%	371.6%	2130.0%
Non-recurring items [+]				78.9
In-process research & development				78.9
Interest expense, net [+]	-2.1	0.0	-1.1	3.1	0.0
Interest expense	27.3	6.8	4.6	4.2	0.0
Interest income	2.1	0.0	1.1	1.1
Other income (expense), net [+]	23.8	5.9	3.3	-145.8	0.0
Change in fair value of warrants			-0.1	-96.3
Other	-1.3	-0.8	-0.3	0.0
Pre-tax income	-197.7	-143.9	-129.1	-255.1	-1.3
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-197.7	-143.9	-129.1	-255.1	-1.3

Basic EPS [+]	($5.05)	($3.89)	($3.88)	($22.45)	($0.21)
Growth	30.0%	0.1%	-82.7%	10445.8%
Diluted EPS [+]	($5.05)	($3.89)	($3.88)	($22.45)	($0.21)
Growth	30.0%	0.1%	-82.7%	10445.8%

Shares outstanding (basic) [+]	39.1	37.0	33.2	11.4	6.1
Growth	5.7%	11.4%	192.3%	87.8%
Shares outstanding (diluted) [+]	39.1	37.0	33.2	11.4	6.1
Growth	5.7%	11.4%	192.3%	87.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.